Clinical and Translational Oncology

, Volume 14, Issue 6, pp 452–457

Biological markers of cisplatin resistance in advanced testicular germ cell tumours

  • Adelaida García-Velasco
  • Ignacio Durán
  • Elena García
  • Miquel Tarón
  • Claudio Ballestín
  • Daniel Castellanos
  • Hernán Cortés-Funés
  • Luis Paz-Ares
Research Articles

Abstract

Introduction

Germ cell tumours (GCTs) of the testis show exquisite sensitivity to treatment with cisplatin. Despite the high cure rates provided by platinum-based chemotherapy, 10–20% of patients die from progressive disease. Although various cellular pathways may influence cisplatin efficacy, their actual impact has not been comprehensively investigated in advanced GCTs. The objective of the present study was to clarify the role of the expression status of proteins involved in the Rb and p53 tumour suppressor pathways in sensitivity and resistance of GCTs to cisplatinbased chemotherapy.

Materials and methods

Paraffin-embedded tumour tissues from 84 patients with advanced GCT treated with cisplatinbased chemotherapy were analysed. Immunohistochemical expression of proteins p53 and mdm2, and the G1-phase cyclins D1 and D2 (CD1 and CD2) was assessed and correlated with the clinical course.

Results

The percentages of positive expression of p53, mdm2, CD1 and CD2 were 56, 57, 37.5 and 55%, respectively. From univariate analysis, there was no significant association between p53, mdm2 or CD1 expression and outcome. Instead, positive CD2 expression was found to be marginally associated with shorter median duration of progression-free survival (PFS) (p=0.06). In multivariate analysis, none of the molecular markers retained statistical significance with treatment response or survival.

Conclusions

Tissular expression of p53, mdm2 and CD1 is not associated with prognosis or treatment response in patients with advanced GCT. Aberrant CD2 expression appears to further determine a shorter PFS. Larger and further studies are required to validate CD2 as a marker of cisplatin resistance.

Keywords

p53 mdm2 Cyclins Testicular cancer Cisplatin resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ries LAG, Eisner MP, Kosary CL et al (eds) (2003) SEER Cancer Statistics Review, 1975–2000. National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2000 Google Scholar
  2. 2.
    Sant M, Aareleid T, Berrino F et al and the EUROCARE Working Group (2004) EUROCARE-3: survival of cancer patients diagnosed 1990-94, results and commentary. Ann Oncol 14[Suppl 5]: v61–v118Google Scholar
  3. 3.
    Bosl GJ, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337:242–253PubMedCrossRefGoogle Scholar
  4. 4.
    Mayer F, Honeker F, Looijenga LHJ et al (2003) Towards an understanding of biological basis of response to cisplatin based chemotherapy in germ cell tumors. Ann Oncol 14:825–832PubMedCrossRefGoogle Scholar
  5. 5.
    Chaganti RSK, Rodríguez E, Bosl GJ (1993) Cytogenetics of male germ cell tumors. Urol Clin North Am 20:55–66PubMedGoogle Scholar
  6. 6.
    Durán I, Garcia-Velasco A, Ballestín C et al (2010) Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clin Transl Oncol 12:443–449PubMedCrossRefGoogle Scholar
  7. 7.
    Kersemaekers AM, Mayer F, Molier M et al (2002) Role of p53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20:1551–1561PubMedCrossRefGoogle Scholar
  8. 8.
    Chaganti RSK, Houldsworth J (1988) The cytogenetic theory of the pathogenesis of human adult male germ cell tumors. Acta Pathol Microbiol Immunol Scand 106:80–84Google Scholar
  9. 9.
    Korkola JE, Houldsworth J, Bosl GJ, Chaganti RS (2009) Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. BJU Int 104:1334–1338PubMedCrossRefGoogle Scholar
  10. 10.
    May M, Peters G (1996) Genetic alterations of cyclins, cyclin dependent kinases, and cdk inhibitors in human cancer. Adv Can Res 68:67–108CrossRefGoogle Scholar
  11. 11.
    Di Pietro A, De Vries EGE, Gietema JA et al (2005) Testicular germ cell tumors: the paradigm of chemo-sensitive solid tumors. Int J Biochem Cell Biol 37:2437–2456PubMedCrossRefGoogle Scholar
  12. 12.
    Mostofi FK, Sesterhenn IA (2005) Histological typing of testis tumors. WHO International Histological Classification of Tumors, 2nd edn. Springer, BerlinGoogle Scholar
  13. 13.
    Bosl GJ, Bajorin D, Sheinfeld J, Motzer R (1995) Cancer of the testis. In: De-Vita VT, Hellman S, Rosenberg S (eds) Cancer, principles and practice of oncology, 5th edn. J.B. Lippincot, Philadelphia, pp 1397–1425Google Scholar
  14. 14.
    Keyomarsi K, Tucker SL, Buchholz TA et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575PubMedCrossRefGoogle Scholar
  15. 15.
    Guillou L, Estreicher A, Chaubert P et al (1996) Germ cell tumors of the testis over-express wildtype p53. Am J Pathol 149:1221–1228PubMedGoogle Scholar
  16. 16.
    Kerley-Hamilton JS, Pike AM, Li N et al (2005) A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 24:6090–6100PubMedCrossRefGoogle Scholar
  17. 17.
    Voorhoeve PM, le Sage C, Schrier M et al (2005) A genetic screen implicates mi-RNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124:1169–1181CrossRefGoogle Scholar
  18. 18.
    Bartkova J, Bartek J, Lucas J et al (1991) p53 protein alterations in human testicular cancer including pre-invasive intratubular germ cell neoplasia. Int J Cancer 49:196–202PubMedCrossRefGoogle Scholar
  19. 19.
    Eid H, Van Der Loou M, Institoris E et al (1997) Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res 17:2663–2670PubMedGoogle Scholar
  20. 20.
    Ulbright TM, Orazi A, deRiese W et al (1994) The correlation of p53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis. Mod Pathol 7:64–68PubMedGoogle Scholar
  21. 21.
    Eid H, Geczi L, Magori A et al (1998) Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53 and metallothionein (MT) proteins. Anticancer Res 18:3059–3064PubMedGoogle Scholar
  22. 22.
    Eid H, Institoris E, Geczi L et al (1999) Mdm-2 expression in human testicular germ-cell tumors and its clinical value. Anticancer Res 19:3485–3490PubMedGoogle Scholar
  23. 23.
    Kukoski R, Blonigen B, Macri E et al (2003) p27 and CyclinE/D2 associations in testicular germ cell tumors. Appl Immunohistochem Mol Morphol 11:138–143PubMedCrossRefGoogle Scholar
  24. 24.
    Bai M, Tsanou E, Agnantis NJ et al (2004) Proliferation profile of classical Hodgkin’s lymphomas. Increased expression of the protein cyclin D2 in Hodgkin’s and Reed Sternberg cells. Mod Pathol 17:1338–1345PubMedCrossRefGoogle Scholar
  25. 25.
    Noel EE, Yeste-Velasco M, Mao X et al (2010) The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol 176:2607–2615PubMedCrossRefGoogle Scholar
  26. 26.
    Bartkova J, Rajpert-De Meyts E, Skakkebæk NE et al (1999) D-Type cyclins in adult human testis and testicular cancer: relation to cell type, proliferation, differentiation, and malignancy. J Pathol 187:573–581PubMedCrossRefGoogle Scholar
  27. 27.
    Houldsworth J, Reuter V, Bosl GJ et al (1997) Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ 8:293–299PubMedGoogle Scholar
  28. 28.
    Schmidt BA, Rose A, Steinhoff C et al (2001) Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclindependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res 61:4124–4221Google Scholar

Copyright information

© FESEO 2012

Authors and Affiliations

  • Adelaida García-Velasco
    • 1
  • Ignacio Durán
    • 1
  • Elena García
    • 1
  • Miquel Tarón
    • 2
  • Claudio Ballestín
    • 3
  • Daniel Castellanos
    • 3
  • Hernán Cortés-Funés
    • 3
  • Luis Paz-Ares
    • 4
  1. 1.Centro Integral Oncológico Clara CampalHospital Norte de Madrid SanchinarroMadridSpain
  2. 2.Laboratorio de InvestigaciónHospital Germans Trias y PujolsBadalona, BarcelonaSpain
  3. 3.Hospital Universitario 12 de OctubreMadridSpain
  4. 4.Hospital Universitario Virgen del RocíoSevillaSpain

Personalised recommendations